Kenvue Inc header image

Kenvue Inc

KVUE

Equity

ISIN null / Valor 124280948

New York Stock Exchange, Inc (2025-11-21)
USD 16.64+3.03%

Kenvue Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Kenvue Inc is a consumer health company that develops, manufactures, and markets over-the-counter medicines and wellness products.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (21.10.2025):

Kenvue Inc. announced its financial results for the second quarter of 2025, highlighting a decrease in net and organic sales. The company is undertaking strategic reviews and leadership changes to accelerate profitable growth, while also revising its full-year outlook in response to current market conditions.

Net Sales Decline

Net sales for Q2 2025 decreased by 4.0% compared to the same period last year, primarily driven by a 4.2% decline in organic sales. This decline was partially offset by a 0.3% benefit from foreign currency fluctuations.

Earnings Per Share

The diluted earnings per share for the quarter were $0.22, up from $0.03 in the prior year period. However, the adjusted diluted earnings per share slightly decreased to $0.29 from $0.32 year-over-year.

Margins and Profitability

Gross profit margin contracted to 58.9% from 59.1% year-over-year, while the adjusted gross profit margin decreased to 60.9% from 61.6%. Operating income margin improved significantly to 18.0% from 3.9%, though the adjusted operating income margin remained relatively stable at 22.7% compared to 22.8%.

Leadership Changes

Kirk Perry was appointed as Interim Chief Executive Officer effective July 14, 2025, following the appointment of Amit Banati as the new Chief Financial Officer. Additionally, Anindya Dasgupta was named Group President, Asia Pacific, and Michael Wondrasch will serve as the new Chief Technology & Data Officer starting August 25, 2025.

Revised Full-Year Outlook

Kenvue has revised its full-year 2025 outlook, expecting net sales and organic sales to decrease in the low-single digits with a neutral impact from foreign currency. The company also anticipates a decline in adjusted operating income margin and projects adjusted diluted earnings per share to be between $1.00 and $1.05.

Summarized from source with an LLMView Source

Key figures

-30.9%1Y
%3Y
%5Y

Performance

33.6%1Y
29.5%3Y
29.5%5Y

Volatility

Market cap

31879 M

Market cap (USD)

Daily traded volume (Shares)

46,900,013

Daily traded volume (Shares)

1 day high/low

21.45 / 21.18

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Roche Holding Ltd
Roche Holding Ltd Roche Holding Ltd Valor: 1203204
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.22%CHF 315.60
Straumann Holding Ltd
Straumann Holding Ltd Straumann Holding Ltd Valor: 117544866
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.30%CHF 96.58
National Healthcare Corp
National Healthcare Corp National Healthcare Corp Valor: 836282
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.42%USD 130.44
Maternus-Kliniken AG
Maternus-Kliniken AG Maternus-Kliniken AG Valor: 335800
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.94%EUR 1.05
Dyne Therapeutics Inc
Dyne Therapeutics Inc Dyne Therapeutics Inc Valor: 56806425
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.27%USD 21.18
Boiron SA
Boiron SA Boiron SA Valor: 487646
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.95%EUR 26.60
COSMO Pharmaceuticals N.V.
COSMO Pharmaceuticals N.V. COSMO Pharmaceuticals N.V. Valor: 32590356
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.45%CHF 67.10
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA SCHOTT Pharma AG & Co. KGaA Valor: 128964250
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.66%EUR 18.44
Coloplast A/S
Coloplast A/S Coloplast A/S Valor: 20259063
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.55%DKK 580.20
MannKind Corp
MannKind Corp MannKind Corp Valor: 35935511
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.21%USD 5.03